|Bid||0.4950 x 1400|
|Ask||0.5640 x 800|
|Day's Range||0.4913 - 0.5500|
|52 Week Range||0.4600 - 2.8100|
|Beta (5Y Monthly)||1.25|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 14, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.38|
Subscribe to Yahoo Finance Plus to view Fair Value for INFI
CAMBRIDGE, Mass., November 22, 2022--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that the Company will present and conduct 1-on-1 meetings with investors at the Piper Sandler 34th Annual Healthcare Conference taking place November 29 – December 1, 2022 in New York.
The heavy selling pressure might have exhausted for Infinity (INFI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Infinity Pharmaceuticals ( NASDAQ:INFI ) Third Quarter 2022 Results Key Financial Results Net loss: US$10.7m (flat on...